PALM BEACH GARDENS, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. ( ZIMV ) (“ZimVie”), a global life sciences leader in the dental implant market, today announced that ARCHIMED, an investment firm focused exclusively on healthcare industries, has completed its previously announced acquisition of ZimVie ( ZIMV ).

Pursuant to the terms of the transaction announced on July 20, 2025, ARCHIMED acquired all of the outstanding shares of ZimVie ( ZIMV ) stock. ZimVie ( ZIMV ) stockholders are entitled to receive $19.00 in cash for each share of ZimVie ( ZIMV ) common stock owned. As a result of the transaction completion, ZimVie’s common stock no longer trades on the NASDAQ stock exchange.

“We are excited to partner with ZimVie ( ZIMV ) to accelerate its growth as a global leader in the dental implant market,” said André-Michel Ballester, Managing Partner at ARCHIMED. “ZimVie’s proven innovation, trusted brand, and strong clinical heritage align perfectly with ARCHIMED’s mission to support world-class healthcare companies.”

Centerview Partners served as exclusive financial advisor to ZimVie ( ZIMV ), and Cravath, Swaine & Moore LLP served as legal advisor. UBS Investment Bank served as exclusive financial advisor to ARCHIMED, and Latham & Watkins LLP served as legal advisor.

About ZimVie ( ZIMV )

ZimVie ( ZIMV ) is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie ( ZIMV ) works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie ( ZIMV ) is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie ( ZIMV ), please visit us at www.ZimVie.com. Follow @ZimVie ( ZIMV ) on Twitter, Facebook, LinkedIn, or Instagram.

About ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. For more information about ARCHIMED, please visit www.archimed.group.

Media Contact Information:

ARCHIMED

Stéphanie Du Ché • [email protected]

(+33) 6 16 36 11 08

ZimVie ( ZIMV )

Grace Flowers • [email protected]

(561) 319-6130

Investor Contact Information:

Gilmartin Group LLC

Webb Campbell • [email protected]

Image: https://www.globenewswire.com/newsroom/ti?nf=OTU0ODM1OSM3MjAzMjU1IzIyMjQ0NTE=

Image: https://ml.globenewswire.com/media/NjA3ZjdjMTMtMTc2Yy00MGM2LWE0MmEtMGZlM2U5N2MxNGQ0LTEyMzYwMDQtMjAyNS0xMC0yMC1lbg==/tiny/ZimVie-Inc-.png Image: Primary Logo

Source: ZimVie Inc. ( ZIMV )